Kavanagh J J, Verschraegen C F, Kudelka A P
Section of Gynecologic Medical Oncology, UT M.D. Anderson Cancer Center, Houston, Texas, USA.
Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):94-8.
Several studies have evaluated the use of irinotecan (CPT-11 [Camptosar]), a topoisomerase inhibitor, in the treatment of refractory or recurrent cervical cancer. Various schedules have been used. Response rates have ranged from 13% to 20%. One phase I study of the combination of cisplatin (Platinol) and irinotecan has been completed. Toxicities have been hematologic and gastrointestinal. The latter remains problematic. Further studies of irinotecan in combination with other drugs, particularly cisplatin, are recommended.
